Lapatinib plus capecitabine in breast cancer [5]

New England Journal of Medicine

Volumn 356, Issue 14, 2007, Pages 1471-1472

  Sonpavde, Guru ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENTIATION; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; BREAST TUMOR; DRUG ANTAGONISM; NOTE; TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 34047248199     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070182     Document Type: Letter

References (1)

1. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.